Welcome to our dedicated page for Pheton Holdings SEC filings (Ticker: PTHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Brachytherapy planning isn’t just technically demanding—it’s capital intensive. When investors ask, “Where does Pheton Holdings spend its R&D budget?” or “How do pending FDA reviews affect cash flow?”, the answers live inside the company’s SEC filings. Stock Titan gathers every 10-K, 10-Q, 8-K material event, and Pheton Holdings insider trading Form 4 transactions the moment they hit EDGAR, so you don’t have to sift through multiple sources.
Navigate straight to the details you search for most: the Pheton Holdings quarterly earnings report 10-Q filing that breaks out software licensing revenue, the proxy statement that lists executive compensation tied to FTTPS milestones, or the 8-K that flags trial-site expansions. Our AI-powered summaries translate dense technical language—“organs at risk dose constraints” or “510(k) submission timelines”—into plain English, making understanding Pheton Holdings SEC documents with AI both fast and accurate. Need alerts on Pheton Holdings Form 4 insider transactions real-time? They’re delivered instantly so you can monitor management’s confidence before key announcements.
Whether you’re tracking development costs hidden deep in an annual report, comparing quarter-over-quarter licensing growth, or checking a Pheton Holdings executive stock transactions Form 4, every filing is searchable, summarized, and linked to original pages. Investors use these insights to gauge regulatory risk, validate revenue projections, and spot emerging trends in radiation oncology. Stock Titan turns a 250-page Pheton Holdings annual report 10-K simplified into actionable insight—so you can focus on decisions, not document hunting.
Pheton Holdings Ltd (PTHL) submitted a Form 6-K related to its 2025 Annual General Meeting of Shareholders. The filing primarily serves to furnish key shareholder materials for that meeting.
The submission includes the notice and proxy statement for the annual meeting, as well as the Third Amended and Restated Memorandum of Association and Third Amended and Restated Articles of Association of iTonic Holdings Ltd. The report is signed by Chief Executive Officer and Chairman Jianfei Zhang on behalf of the company.
Pheton Holdings Ltd reported governance changes. Independent director Edward C Ye resigned effective immediately for personal reasons, with no disagreement cited. The board appointed Richard Wee Yong Seow as an independent director, and named him to the Audit, Nomination & Corporate Governance, and Compensation Committees. He will replace Swee Leng Seng as chair of the Compensation Committee, while Mr. Swee Leng Seng becomes chair of the Audit Committee. The Company states Mr. Seow meets Nasdaq and SEC independence standards, and Mr. Swee Leng Seng is an SEC-defined “audit committee financial expert.” The Company entered into an indemnification agreement with Mr. Seow.
Pheton Holdings Ltd (PTHL) reported it received a Nasdaq notice that its Class A ordinary shares failed the minimum bid price requirement under Listing Rule 5550(a)(2) after trading below $1.00 for 30 consecutive business days. The notice does not trigger immediate delisting, and the shares continue trading under “PTHL.”
The company has 180 calendar days, until April 20, 2026, to regain compliance. If the closing bid is at least $1.00 for a minimum of 10 consecutive business days during this period, Nasdaq will confirm compliance. If compliance is not regained by that date, Pheton may qualify for an additional 180‑day grace period if it meets other Nasdaq Capital Market initial listing standards (except bid price) and notifies Nasdaq of its plan to cure, which may include a reverse stock split.
FAQ
What is the current stock price of Pheton Holdings (PTHL)?
What is the market cap of Pheton Holdings (PTHL)?
